Dr Mead on the Decreased Use of Ibrutinib in Pretreated MCL
Monica D. Mead, MD, discusses reasons for the declining use of the BTK inhibitor ibrutinib in patients with mantle cell lymphoma.
Source: onclive.com
Page 2 - Hematologic Malignancy News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Hematologic Malignancy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Hematologic Malignancy Today - Breaking & Trending Today
Dr Mead on the Shifting Role of Ibrutinib in the Treatment of MCL
Monica D. Mead, MD, discusses the impact of key data on the role of ibrutinib in the treatment of mantle cell lymphoma.
Source: onclive.com
Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma
Monica D. Mead, MD, discusses the evolving use of the BTK inhibitors in the treatment of patients with MCL, the factors for selecting between ibrutinib, zanubrutinib, and acalabrutinib, and unmet needs for patients with MCL
Source: onclive.com
Quizartinib improves overall median survival in patients with acute myeloid leukemia
1. Overall survival in the quizartinib group was 31.9 months compared to 15.1 months in the placebo group. 2. Proportion of adverse events in both groups was comparable between groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Acute myeloid leukemia (AML) is an aggressive form of blood cancer with poor clinical outcomes. In patients with
Source: 2minutemedicine.com
GRAIL, LLC: GRAIL Presents New Data Demonstrating That Methylation Assay Detects Residual Hematologic Cancer After Treatment at American Association for Cancer Research (AACR) Annual Meeting 2023
GRAIL's Methylation Assay Had 92% Cancer Detection Rate Across Six Hematologic Malignancies With 96% Accuracy in Determining the Hematologic Malignancy Subtype Findings Support Use of GRAIL's Methylation
Source: finanznachrichten.de